

**Product Name** : Lorlatinib

**Synonyms** : PF-06463922; PF 06463922; PF06463922


**Cat No.** : M11964

**CAS Number** : 1454846-35-5

**Molecular Formula** : C<sub>21</sub>H<sub>19</sub>FN<sub>6</sub>O<sub>2</sub>

**Formula Weight** : 406.41

**Chemical Name** : 2H-4,8-Methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-



**Description** : A novel CNS-penetrant, ATP-competitive inhibitor of ALK/ROS1 with IC<sub>50</sub> of 0.07/0.025 nM respectively; also inhibits ALK L1196M (IC<sub>50</sub>=0.7 nM) and exhibits selectivity >100-fold for ROS1 over 204 kinases; inhibits crizotinib-resistant mutant ROS1G2032R and ROS1L2026M and orally available in vivo. Lung Cancer Phase 3 Clinical

**Pathway** : Angiogenesis

**Target** : ALK

**Receptor** : ALK; ALK(L1196M); LTK(TYK1); ROS1

**Solubility** : DMSO: ≥ 28 mg/mL

**SMILES** : N#CC1=C(C(CN2C)=NN1C)C3=CN=C(N)C(O[C@H](C)C4=CC(F)=CC=C4C2=O)=C3

**Storage** : (-20°C)

**Stability** : ≥ 2 years

**Reference** :

1. Zou HY, et al. Proc Natl Acad Sci U S A. 2015 Mar 17; 112(11):3493-8. | 2. Johnson TW, et al. J Med Chem. 2014 Jun 12; 57(11):4720-44. | 3. Infarinato NR, et al. Cancer Discov. 2016 Jan; 6(1):96-107.